348 related articles for article (PubMed ID: 27432877)
61. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
62. Treatment of Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Curr Treat Options Oncol; 2007 Apr; 8(2):144-53. PubMed ID: 17634838
[TBL] [Abstract][Full Text] [Related]
63. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
64. Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M; Frustaci AM; Deodato M; Cairoli R; Tedeschi A
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018004. PubMed ID: 29326801
[TBL] [Abstract][Full Text] [Related]
65. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
[TBL] [Abstract][Full Text] [Related]
66. Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.
Treon SP; Patterson CJ; Kimby E; Stone MJ
Clin Lymphoma Myeloma; 2009 Mar; 9(1):10-5. PubMed ID: 19362961
[No Abstract] [Full Text] [Related]
67. Diagnosis and management of Waldenstrom's macroglobulinemia.
Dimopoulos MA; Kyle RA; Anagnostopoulos A; Treon SP
J Clin Oncol; 2005 Mar; 23(7):1564-77. PubMed ID: 15735132
[TBL] [Abstract][Full Text] [Related]
68. Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM).
Anagnostopoulos A; Giralt S
Bone Marrow Transplant; 2002 Jun; 29(12):943-7. PubMed ID: 12098060
[TBL] [Abstract][Full Text] [Related]
69. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
[TBL] [Abstract][Full Text] [Related]
70. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
Kimby E; Treon SP; Anagnostopoulos A; Dimopoulos M; Garcia-Sanz R; Gertz MA; Johnson S; LeBlond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone M; Bladé J
Clin Lymphoma Myeloma; 2006 Mar; 6(5):380-3. PubMed ID: 16640813
[TBL] [Abstract][Full Text] [Related]
71. [How can we treat Waldenström's macroglobulinemia?].
Mucsi AO; Nagy Z
Magy Onkol; 2017 Mar; 61(1):12-20. PubMed ID: 28273184
[TBL] [Abstract][Full Text] [Related]
72. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
73. The role of stem cell transplantation in Waldenstrom's macroglobulinemia.
Chakraborty R; Muchtar E; Gertz MA
Best Pract Res Clin Haematol; 2016 Jun; 29(2):229-240. PubMed ID: 27825469
[TBL] [Abstract][Full Text] [Related]
74. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
75. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
76. How Recent Advances in Biology of Waldenström's Macroglobulinemia May Affect Therapy Strategy.
Baron M; Simon L; Poulain S; Leblond V
Curr Oncol Rep; 2019 Feb; 21(3):27. PubMed ID: 30806816
[TBL] [Abstract][Full Text] [Related]
77. Role of proteasome inhibition in Waldenström's macroglobulinemia.
Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
[TBL] [Abstract][Full Text] [Related]
78. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia.
Chen C; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):74-6. PubMed ID: 19362979
[TBL] [Abstract][Full Text] [Related]
79. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Ababneh O; Abushukair H; Qarqash A; Syaj S; Al Hadidi S
Clin Hematol Int; 2022 Jun; 4(1-2):21-29. PubMed ID: 35950210
[TBL] [Abstract][Full Text] [Related]
80. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Lévy V; Morel P; Porcher R; Chevret S; Wattel E; Leblond V
Haematologica; 2005 Feb; 90(2):279-81. PubMed ID: 15710594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
